Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 167,133 | 131,314 | 196,245 | 241,544 | 163,562 |
| Cost of Goods | 11,074 | 10,512 | 52,827 | 62,176 | 30,419 |
| Gross Profit | 156,059 | 120,802 | 143,418 | 179,368 | 133,143 |
| Operating Expenses | 178,739 | 109,372 | 141,208 | 75,693 | 96,062 |
| Operating Income | -22,606 | 11,942 | 3,037 | 103,851 | 37,500 |
| Interest Expense | 3,037 | 656 | 1,799 | 19,619 | 27,415 |
| Other Income | 28,161 | 52,374 | 34,773 | -12,027 | -8,793 |
| Pre-tax Income | 2,518 | 63,660 | 36,011 | 72,205 | 1,292 |
| Income Tax | 6,550 | 9,841 | 41,230 | -4,148 | -5,306 |
| Net Income Continuous | -4,032 | 53,819 | -5,219 | 76,353 | 6,598 |
| Net Income Discontinuous | N/A | -1,665 | -28,142 | -19,215 | -9,583 |
| Net Income | $-4,032 | $52,154 | $-33,361 | $57,138 | $-2,985 |
| EPS Basic Total Ops | -0.22 | 3.02 | -1.98 | 3.44 | -0.18 |
| EPS Basic Continuous Ops | -0.22 | 3.11 | -0.31 | 4.59 | 0.41 |
| EPS Basic Discontinuous Ops | N/A | -0.10 | -1.67 | -1.16 | -0.59 |
| EPS Diluted Total Ops | -0.22 | 2.94 | -1.98 | 3.31 | -0.18 |
| EPS Diluted Continuous Ops | -0.22 | 3.03 | -0.31 | 4.43 | 0.39 |
| EPS Diluted Discontinuous Ops | N/A | -0.09 | -1.67 | -1.11 | -0.57 |
| EPS Diluted Before Non-Recurring Items | -0.22 | 2.91 | 1.94 | 4.65 | 3.13 |
| EBITDA(a) | $11,788 | $47,385 | $55,321 | $171,600 | $90,022 |